Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings - Hummel, Horst-Dieter; Kufer, Peter; Grüllich, Carsten; Seggewiss-Bernhardt, Ruth; Deschler-Baier, Barbara; Chatterjee, Manik; Goebeler, Maria-Elisabeth; Miller, Kurt; de Santis, Maria; Loidl, Wolfgang; Dittrich, Christian; Buck, Andreas; et al. (Immunotherapy, 2021)
Online veröffentlicht: 11. November 2020